PRESS RELEASE

Physiogenex strengthens its offer through a strategic partnership with GAIA nuclear imaging platform.

Toulouse (France), June 28, 2012- Last June, Physiogenex and the Gamma Imaging Applications Platform (GAIA) signed a strategic partnership to work jointly on preclinical studies exploiting GAIA's nuclear molecular imaging facilities and expertise.

Physiogenex's core business focuses on the validation of new drug targets and new potential medicines at preclinical levels. To provide its clients with the best services to help them in the development of their compounds, the company signed an agreement with GAIA to exploit the platform's research and know-how.

GAIA has co-developed a wide range of techniques and procedures for radioactive tracers aimed at both preclinical and clinical nuclear imaging.

The strategic collaboration that has been signed with the GAIA platform will therefore allow Physiogenex to strengthen its services for preclinical studies in the field of metabolic and cardiovascular disorders.

The various services offered to clients will include:

- Radioactive tagging of molecules of interest
- Biodistribution of orginal molecules (how they distribute within the body), and pharmakinetics (i.e. investigate the fate of these molecules over time)
- The evaluation of the efficiency of new therapeutic molecules with validated radiotracers
- Characterization of an animal model of interest. Indeed, several radiotracers are already available to investigate phenotypic alterations (ie. anatomical, morphologic, molecular and functional changes).

Catherine Ghezzi, the Grenoble Small Animal Nuclear Imaging Platform's scientific manager described the value of this new relationship: *"the agreement is a real recognition of our*

expertise in the field of radiostaining and of the biological evaluation of radiotracers and we feel that it will really help to open up the GAIA platform to the private sector. Physiogenex's reputation and service offering in cardiometabolism, which are two key strategic areas of research for GAIA, will be a real vector with regards to the development of our platform".

"Nuclear imaging is becoming increasingly important particularly with regards to drug development. These non-invasive techniques generate mechanistic data, through functional imaging, and assess the efficacy of compounds thanks to the use of follow-up markers. These techniques are indispensible in making our preclinical studies more predictable and give more powerful translational tools for the clinical development. Physiogenex is delighted to announce this strategic partnership which will give our clients access to GAIA platform's extensive expertise and know-how and bring to the biotech/pharma industry an improved and seamless end-to-end offering » said Thierry Sulpice, Scientific & Managing Director of Physiogenex.

For more information on nuclear imaging services, please contact us through our website or on business@physiogenex.com

About Physiogenex - http://www.physiogenex.com
Physiogenex is a preclinical contract research organization providing outstanding services and scientific expertise on metabolic disorders. Physiogenex pioneers the development of kinetic methods using radioactive labeled tracers and predictive animal nutritional models. Physiogenex expertise focuses on type 2 diabetes, dyslipidemia and liver disease, integrating the links between glucose, lipid, lipoprotein metabolism and related cardiovascular complications.

About GAIA Platform - http://www.floralis.fr/us/accueil/floralis_innovation.php
The GAIA platform is part of the ISDV network of ten specialist imaging platforms in Grenoble that are owned by the University Joseph Fourier and accredited by the IBiSA (the body responsible for governing and supporting technology platforms in the field of lifescience). Floralis, the UJF's technology transfer subsidiary has the overall responsibility of promoting and exploiting the commercial capabilities of these platforms. **contact:** marie-gabrielle.jouan@floralis.fr